Paper Review Records
All Paper Review Records
19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
175
days
A Dose‐Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HP501 in Male Chinese Gout Patients with Hyperuricemia
AuthorsLongxia Chen; Ruilin Ding; Yuanwei Chen; Xinghai Li; Tengqiong Xiong; Hong Chen; Xiaojing Hu; Yi Zhou; Feng Jiang; Qing Peng
Affiliations1. Institute of Drug Clinical Trial/GCP Center The Affiliated Hospital of Southwest Medical University Luzhou China; 2. Hinova Pharmaceuticals Inc. Chengdu China; 3. Department of Cardiology The Affiliated Hospital of Southwest Medical University Luzhou China
241
days
A First‐in‐Japanese Phase 1, Double‐Blind, Placebo‐Controlled, Parallel‐Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants
AuthorsTakakazu Sato; Hiroyuki Fukase; Takaaki Ishida; Arisa Karasawa
Affiliations1. Chugai Pharmaceutical Co., Ltd. Tokyo Japan; 2. Clinical Research Hospital Tokyo Japan
277
days
Pharmacokinetic and Pharmacodynamic Bio‐Similarity of ADL‐018 to Innovator Omalizumab: A Randomized Study in Healthy Adults
AuthorsSunil Soitawala; Hiren Prajapati; Hiren Mehta; Pawan Kumar Singh
Affiliations1. Clinical Research Department Veeda Clinical Research Ltd. Mehsana Gujarat India; 2. Clinical Research Department Veeda Clinical Research Ltd. Ahmedabad Gujarat India; 3. Clinical Affairs/Biometrics Department Veeda Clinical Research Ltd. Ahmedabad Gujarat India; 4. Kashiv Biosciences, LLC Ahmedabad Gujarat India
126
days
An Open‐Label Study Investigating the 5‐HT 2A Receptor Occupancy of Remlifanserin (ACP‐204) With the PET Radioligand [ 18 F]Altanserin in Healthy Male Participants
AuthorsEthan S. Burstein; Christine Sandiego; Brian Raether; Xiaoshu Feng; Bryan Dirks; Mona Darwish; Peter Zhang; David S. Russell; Eugenii A. Rabiner; Sanjeev Pathak
Affiliations1. Acadia Pharmaceuticals Inc. San Diego CA USA; 2. Perceptive Discovery New Haven CT USA; 3. Acadia Pharmaceuticals Inc. Princeton NJ USA; 4. Perceptive Discovery London UK
102
days
A Phase 1, Single‐Center, Randomized, Double‐Blind, Placebo‐Controlled, Multiple‐Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu‐pGSN) Following Intravenous Administration to Healthy Volunteers
AuthorsYao Liu; Susan L. Levinson; Edward Kowalik; Jeremy Pronchik; Lester Kobzik; Mark J. DiNubile
Affiliations1. BioAegis Therapeutics North Brunswick NJ USA
133
days
Comparative Bioavailability of a Fixed‐Dose Combination of Etoricoxib and Betamethasone in Healthy Volunteers
AuthorsLourdes Garza‐Ocañas; Christian T. Badillo‐Castañeda; Sandra L. Montoya‐Eguía; María T. Zanatta‐Calderón; Julia D. Torres‐Garza; Pedro Lennon Sáenz‐ Chávez; Kevin F. Rios‐Brito; Pablo E. Morales‐Hernandez; Seydhel C. Reyes‐Granados; Jorge González‐Canudas
Affiliations1. Pharmacology and Toxicology Department Autonomous University of Nuevo Leon Monterrey Mexico; 2. Research and Development Department Laboratorios Silanes, S.A. de C.V. Mexico City Mexico; 3. Mexican Social Security Institute (IMSS) Centro Médico Nacional Siglo XXI Mexico City Mexico
145
days
Bioequivalence of two rabeprazole formulations and pharmacokinetic variability by CYP2C19 genotype and sex in healthy Korean participants: A four‐period replicated crossover study
AuthorsNakyong Lee; Joo‐Youn Cho; Byungwook Kim
Affiliations1. Department of Clinical Medical Sciences Seoul National University College of Medicine Seoul Republic of Korea; 2. Department of Biomedical Sciences Seoul National University College of Medicine Seoul Republic of Korea; 3. Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea; 4. Kidney Research Institute Seoul National University Medical Research Center Seoul Republic of Korea; 5. Department of Pharmacology Kangwon National University School of Medicine Chuncheon Republic of Korea
296
days
Assessment of Pharmacokinetic Interaction and Clinical Efficacy of Clopidogrel Co‐administered with Ilaprazole
AuthorsDamodharan N; Priyadharshini A; Vijayakumar T M; Rajesh N A
Affiliations1. Department of Pharmaceutics SRM College of Pharmacy SRM Institute of Science and Technology Kattankulathur Tamil Nadu India; 2. Department of Pharmacy Practice SRM College of Pharmacy SRM Institute of Science and Technology Kattankulathur Tamil Nadu India; 3. Department of Medical Gastroenterology SRM Medical College Hospital and Research Centre SRM Institute of Science and Technology Kattankulathur Tamil Nadu India
103
days
Bioequivalence Study of Two Ibuprofen Arginine Formulations in Healthy Chinese Subjects Under Fed Conditions
AuthorsYiyang Ying; Chunqi Huang; Li Xu; Yi Wu; Shufan Cai; Lijun Ye; Xiangxin Huang; Lin Wang; Ying Wang
Affiliations1. The First Clinical Medical College Zhejiang Chinese Medical University Hangzhou Zhejiang Province China; 2. Department of Laboratory Medicine The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province Hangzhou Zhejiang China; 3. School of Pharmacy Hangzhou Normal University Hangzhou Zhejiang China; 4. Clinical Research Center Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University Hangzhou China; 5. Zhejiang Key Laboratory of Zero Magnetic Medicine Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University Hangzhou China
214
days
Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial
AuthorsMita Kuchimanchi; Trine Lembrecht Jørgensen; Eva Hanze; Angela Jain; Oskar Alskär; Oleksandr Zub; Mark S. Shahin; Anthoula Koliadi; Bhavana Pothuri; Thomas Krivak; Mikalai Pishchyk; Yakir Segev; Floor J. Backes; Christine Gennigens; Sara Bouberhan; Stefan Zajic; Murad Melhem; Joseph Buscema
Affiliations1. GSK Waltham MA USA; 2. Department of Oncology Odense University Hospital Odense Denmark; 3. qPharmetra Uppsala Sweden; 4. Fox Chase Cancer Center Philadelphia PA USA; 5. Chernihiv Medical Center of Modern Oncology Chernihiv Regional Council Chernihiv Ukraine; 6. Division of Gynecologic Oncology Penn State Hershey Medical Center Hershey PA USA; 7. Department of Gynecologic Oncology Uppsala University Hospital Uppsala Sweden; 8. Nordic Society of Gynaecological Oncology (NSGO) Clinical Trial Unit Copenhagen Denmark; 9. Departments of Obstetrics and Gynecology and Medicine Division of Gynecologic Oncology NYU Langone Health New York NY USA; 10. GOG Foundation Philadelphia PA USA; 11. Division of Gynecologic Oncology The Western Pennsylvania Hospital Pittsburgh PA USA; 12. Grodno Regional Clinical Hospital Grodno Belarus; 13. Carmel Medical Center Technion‐Israel Institute of Technology Haifa Israel; 14. Division of Gynecologic Oncology Ohio State University Columbus OH USA; 15. Department of Medical Oncology CHU of Liège Liège Belgium; 16. Belgium and Luxembourg Gynaecological Oncology Group (BGOG) Leuven Belgium; 17. Massachusetts General Hospital Boston MA USA; 18. Affiliation at time of study GSK Collegeville PA USA; 19. TMC Healthcare Cancer Center Tucson AZ USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days